^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

RPS6KB1 (Ribosomal Protein S6 Kinase B1)

i
Other names: RPS6KB1, Ribosomal Protein S6 Kinase B1, S6K1, Serine/Threonine-Protein Kinase 14A, Ribosomal Protein S6 Kinase Beta-1, Ribosomal Protein S6 Kinase I, P70(S6K)-Alpha, S6K-Beta-1, P70 S6KA, STK14A, PS6K, S6K, Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 1, Ribosomal Protein S6 Kinase, 70kD, Polypeptide 1, 70 KDa Ribosomal Protein S6 Kinase 1, Serine/Threonine Kinase 14 Alpha, P70 Ribosomal S6 Kinase Alpha, P70 S6 Kinase, Alpha, P70 S6 Kinase Alpha, P70 S6K-Alpha, P70-Alpha, P70-S6K 1, P70-S6K, RPS6KB1, P70S6K1
15d
Hsa_circ_0003176: a key player in the m6A modification-mediated regulation of autophagy and glycolysis in cisplatin-resistant non-small cell lung cancer. (PubMed, Hum Cell)
In addition, in vivo xenograft models confirmed that hsa_circ_0003176 overexpression suppressed tumor growth and enhanced DDP sensitivity. Our study reveals the METTL3/m6A/hsa_circ_0003176/RPS6KB1 pathway as a critical pathway in NSCLC chemoresistance, offering novel therapeutic targets for overcoming DDP resistance.
Journal
|
RPS6KB1 (Ribosomal Protein S6 Kinase B1) • RPS6 (Ribosomal Protein S6) • METTL3 (Methyltransferase Like 3)
|
cisplatin
1m
Targeting PAK1 suppresses tumor progression by promoting mRNA decay of oncogenic factors and enhancing chemotherapeutic efficacy in colorectal cancer. (PubMed, Genes Dis)
Importantly, our results revealed that the PAK1 inhibitor, PF3758309, exhibited a profound synergistic effect with oxaliplatin in CRC. Collectively, our study unveils a novel function of PAK1 in CRC progression. Thus, these results highlight the potential of targeting PAK1 as a therapeutic strategy in CRC, particularly in combination with oxaliplatin.
Journal
|
CD44 (CD44 Molecule) • SAA1 (Serum Amyloid A1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • PAK1 (p21 (RAC1) activated kinase 1) • EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1)
|
oxaliplatin • PF-3758309
2ms
Effects of miR-128-3p on Renal Inflammation in a Rat Periodontitis Model. (PubMed, Dent J (Basel))
The potential target genes of activin A receptor type I (Acvr1), ribosomal protein S6 kinase B1 (Rps6kb1), and transforming growth factor beta receptor type 1 (Tgfbr1) were significantly lower in the kidneys of the LPS group. EVs-derived miR-128-3p in LPS induced periodontitis may cause kidney inflammation which may be mediated by, Rps6kb1, Tgfbr1, and Acvr1.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • ACVR1 (Activin A Receptor Type 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • RPS6 (Ribosomal Protein S6) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • MIR128 (MicroRNA 128) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
2ms
BCAA (Branched-Chain Amino Acids) Inhibiting the Autophagy System via the Activation of mTORC1, Thereby Upregulating the Tumor Suppressor PDCD4 in Huh7 Hepatoma Cells. (PubMed, Cells)
Additionally, BCAA upregulated the phosphorylation of ULK1 at serine 757, which was inhibited by rapamycin...Furthermore, FACS analysis showed that BCAA inhibited the proliferation of Huh7 cells. BCAA may have a preventive effect against tumor development through the modulation of autophagy and the tumor suppressor pathways.
Journal
|
EGF (Epidermal growth factor) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)
|
sirolimus
4ms
Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma. (PubMed, Lung Cancer)
This comprehensive transcriptomic characterization of T-cell exclusion in PM reveals that targeting cilium-based Hedgehog signaling, in addition to multiple other actionable drug targets, could enhance the efficacy of ICB treatment in PM.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • SMO (Smoothened Frizzled Class Receptor) • ACVR1 (Activin A Receptor Type 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CMTM4 (CKLF Like MARVEL Transmembrane Domain Containing 4) • KDM5B (Lysine Demethylase 5B) • SOX4 (SRY-Box Transcription Factor 4) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
6ms
An integrated environmental toxicity risk assessment framework combining deep learning and molecular simulation: A case study on pyrethrins and breast cancer. (PubMed, Biochem Biophys Rep)
This integrative methodology supports environmental exposure monitoring and toxicological policy development. The open-source, containerized analytical toolchain developed herein is highly extensible and adaptable for future toxicological evaluations of other natural compounds and emerging environmental pollutants.
Journal
|
ER (Estrogen receptor) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)
|
ER positive
7ms
Gene fusion detection in long-read transcriptome sequencing data with GFvoter. (PubMed, BMC Genomics)
Overall, our findings show that GFvoter can accurately identify gene fusions from long-read RNA-seq data, which has the potential to improve cancer diagnosis and treatment. GFvoter is available at https://github.com/xiaolan-z/GFvoter .
Journal
|
RPS6KB1 (Ribosomal Protein S6 Kinase B1) • VMP1 (Vacuole Membrane Protein 1)
7ms
Novel kinase-activating genetic events in non-small cell lung carcinomas. (PubMed, Explor Target Antitumor Ther)
ROS1, LTK, and FGFR4 high-level overexpression was observed in 1 out of 89 tumors each. This study demonstrates the scarcity of yet unknown kinase-activating alterations in NSCLCs.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • FGFR4 (Fibroblast growth factor receptor 4) • LTK (Leukocyte Receptor Tyrosine Kinase) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CLIP1 (CAP-Gly Domain Containing Linker Protein 1) • KAT6B (Lysine Acetyltransferase 6B) • VMP1 (Vacuole Membrane Protein 1)
8ms
Oxocrebanine inhibits the proliferation of hepatocellular carcinoma cells by promoting apoptosis and autophagy. (PubMed, World J Gastrointest Oncol)
Oxocrebanine can inhibit the proliferation of human hepatocellular carcinoma cells by promoting apoptosis and inducing autophagy in vitro and in vivo.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • CASP3 (Caspase 3) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)
9ms
S6K1 overexpression enhances autophagy in breast cancer cells by inducing the translation of CLU. (PubMed, Chin Med J (Engl))
This study demonstrated that the overexpression of S6K1 promoted autophagy in breast cancer cells by facilitating the translation of the autophagy-related gene CLU.
Journal
|
RPS6KB1 (Ribosomal Protein S6 Kinase B1) • CLU (Clusterin) • RPS6 (Ribosomal Protein S6)
10ms
Comprehensive genomic profiling reveals a unique genomic landscape in solid tumors in an Indian cancer cohort of 1000 patients: a single institutional experience. (PubMed, Sci Rep)
The overall change in therapy based on CGP in the clinical cohort was 43%, which was greater in patients enrolled for MTB than in patients who had not undergone MTB. At the interim analysis, with a median follow-up of 18 months (range 12-24 months) after the change in therapy as per genomics report, 97 patients (71%) were found to be alive thus establishing the importance of CGP and MTB in personalized genomics-driven treatment.
Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • EML4 (EMAP Like 4) • HRD (Homologous Recombination Deficiency) • ARID1A (AT-rich interaction domain 1A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • BRCA (Breast cancer early onset) • ARID2 (AT-Rich Interaction Domain 2) • RPS6KB1 (Ribosomal Protein S6 Kinase B1) • NTRK (Neurotrophic receptor tyrosine kinase) • VMP1 (Vacuole Membrane Protein 1)
|
BRCA mutation
10ms
Activating autophagy to eliminate toxic protein aggregates with small molecules in neurodegenerative diseases. (PubMed, Pharmacol Rev)
Moreover, we underscore the activation of autophagy as a potential therapeutic strategy across different NDs and small molecules capable of activating autophagy pathways, such as rapamycin targeting the mTOR pathway to clear α-synuclein and Sertraline targeting the AMPK/mTOR/RPS6KB1 pathway to clear Tau, to further illustrate their potential in NDs' therapeutic intervention. It also elucidates the fascinating interrelationships between toxic proteins and the process of autophagy of "chasing and escaping" phenomenon. Moreover, the review further discusses the progress utilizing small molecules to activate autophagy to improve the efficacy of therapies for neurodegenerative diseases by removing toxic protein aggregates.
Review • Journal
|
TARDBP (TAR DNA Binding Protein) • RPS6KB1 (Ribosomal Protein S6 Kinase B1)
|
sirolimus